Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Filings indexed 336 across all filing types
Latest filing 2021-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Celltrion Pharm, Inc. for the period of January 1, 2021, to March 31, 2021. It contains detailed financial information, business overviews, capital changes, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-14 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding a change in the company's market classification (from 'Mid-sized Enterprise' to 'Blue-chip Enterprise') on the stock exchange. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company status, it falls under the RNS category.
2021-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific individual (Kwon Seok) at Celltrion Pharm. This is a standard regulatory filing for insider trading/shareholding reporting, which falls under the 'Director's Dealing' category.
2021-04-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is a standard regulatory disclosure for insider share ownership changes, which falls under the 'Director's Dealing' category in the provided schema.
2021-04-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is a mandatory disclosure for company insiders (directors/executives) to report their personal shareholdings and changes therein. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2021-04-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard South Korean regulatory form (DART filing) used by company insiders to disclose their shareholdings and changes therein. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions and ownership status by a company executive.
2021-04-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.